Investigators shared data at an oncology meeting last week, showing that the test has high sensitivity and specificity in a blinded case-control cohort that included early-stage tumors.
Guardant's lab will make Guardant360 available to doctors and their patients in the region to help identify patients eligible for molecularly targeted drugs.
The study supports the use of liquid biopsy tests to guide treatment decisions, especially in patients who can't be biopsied, or don't have enough tissue available for standard testing.
The company has developed a technology for isolating cancer DNA in urine along with specialized PCR assays to identify biomarkers that it believes will offer more accurate and sensitive detection of hepatocellular carcinoma.
The partners aim to optimize DNA nanoball technology, accelerate the use of CTC technology, and work on a diagnostic tool for use at the point of care.
